Events & Ideas

Judy Ashworth, MD, Vice President, Rx Strategic Services and Chief Medical Officer, Pinney Associates These comments are submitted in response to the Federal Register notice Standards for Future Opioid Analgesic Approvals and Incentives for New Therapeutics to Treat Pain and Addiction, Docket FDA-2019-N-2514. This is a written version of comments made orally at the September… Read More

Henningfield JE, Ashworth J, Gerlach KK, Simone B, Schnoll SH Preventive Medicine, 128:10582, 2019. Special Issue on Opioids Addiction and Pain, 2019. Pain and addiction are complex disorders with many commonalities. Beneficial outcomes for both disorders can be achieved through similar principles such as individualized medication selection and dosing, comprehensive multi-modal therapies, and judicious modification… Read More

Johnson M, Griffiths R, Hendricks P, Henningfield JE Neuropharmacology, 142:143-166, 2018. This review assesses the abuse potential of medically administered psilocybin, following the structure of the 8 factors of the US Controlled Substances Act (CSA). Research suggests the potential safety and efficacy of psilocybin in treating cancer-related psychiatric distress and substance use disorders, setting the… Read More

Belouin S, Henningfield JE Neuropharmacology, 142:7-19, 2018. The purpose of this commentary is to provide an introduction to this special issue of Neuropharmacology with a historical perspective of psychedelic drug research, their use in psychiatric disorders, research-restricting regulatory controls, and their recent emergence as potential breakthrough therapies for several brain-related disorders. It begins with the… Read More